Natera Inc.
Natera Announces Preliminary 2025 Financial Results with Strong Growth
Summary
On January 11, 2026, Natera, Inc. released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company reported total revenues of approximately $660 million for the fourth quarter, a 39% increase from the previous year, and $2.3 billion for the full year, a 35% increase. The company processed about 923,600 tests in the fourth quarter and 3,525,500 tests for the full year, with significant growth in oncology tests, particularly clinical molecular residual disease (MRD) tests. Despite the strong financial performance, cash inflows were approximately $30 million for the fourth quarter and over $100 million for the full year. These results will be detailed further during the company's earnings call in February 2026.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement